HESKA RESTR. NEW DL-,001

ATHENS, Ga.--(BUSINESS WIRE)--Dalan Animal Health, Inc. (“Dalan”), the biotech company pioneering insect health with the world’s first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical component of agriculture. One-third of the global food supply relies on pollination, and healthy commercial hives are essential to secure high crop yields. However, honeybee colonies are plagued by American Foulbrood, with previously no safe and sustainable solution for disease prevention. Overt clinical cases of American Foulbrood are notifiable in the USA and Canada, and the only treatment method to limit the further spread of disease to other colonies relies on the incineration of bees and infected hives and equipment. Tauzer, also a board member of the California State Beekeepers Association, said, “We are excited about the arrival of Dalan's honey bee vaccine. This innovative solution will help honeybees prevent infection, avoid treatments, and focus on other crucial aspects of maintaining our bee's health”. Tauzer plans to sell vaccinated queen bees through his queen-producing operation, Honey Bee Genetics, beginning this year. Queens can be purchased at honeybeegenetics.com Dr. Annette Kleiser, CEO of Dalan Animal Health, emphasized the importance of the vaccine, stating, “Our mission is to protect our pollinators and promote sustainable agriculture. As global population growth and climate change continue, honeybee pollination will be increasingly vital to secure our food supply. This vaccine is a game-changer in safeguarding honeybees, and we're excited to be at the forefront of revolutionizing insect care, which will ultimately impact global food production.” Beekeepers interested in safeguarding their colonies with Dalan's vaccine can visit the website at https://www.dalan.com/contact or call 844-483-2526. The honey bee vaccine, manufactured by Diamond Animal Health (Des Moines, IA), a wholly-owned subsidiary of Heska (NASDAQ: HSKA), will initially be distributed on a limited basis to commercial beekeepers and queen producers. About the vaccine Dalan's vaccine uses killed whole-cell Paenibacillus larvae bacteria and is administered by mixing it into queen feed consumed by worker bees. The vaccine is incorporated into the royal jelly by the worker bees, who then feed it to the queen. The queen ingests the vaccine, and fragments are deposited in her ovaries, providing immunity to the developing larvae. The non-GMO vaccine can be used in organic agriculture, and pivotal efficacy studies have shown its potential to reduce larval death associated with American Foulbrood infections caused by P. larvae. About Dalan Animal Health, Inc Dalan Animal Health (www.dalan.com) is dedicated to preventing diseases that affect invertebrates, increasing profitability and yield for producers worldwide. This platform technology uses transgenerational immune priming, allowing the maternal animal to pass immune modulators (e.g., antigens, anti-microbial molecules) to the next generation larvae before they hatch. Dalan plans to develop vaccines for other honeybee diseases and underserved industries, such as shrimp, mealworms, and insects used in agriculture. The company is headquartered in Athens, Georgia, at the University of Georgia’s Innovation Hub.» Mehr auf businesswire.com

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Heska Corporation (NasdaqCM: HSKA) to Mars, Incorporated. Under the terms of the proposed transaction, shareholders of Heska will receive $120.00 in cash for each share of Heska that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-hska/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.» Mehr auf businesswire.com

Heska (HSKA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.27 per share a year ago.» Mehr auf zacks.com